M&A Fireworks: Shire Buys Jerini For €328 Million
This article was originally published in The Pink Sheet Daily
Executive SummaryJerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”
You may also be interested in...
FDA questioned the validity of icatibant’s patient-reported outcomes instrument during a first-cycle review and found it “difficult to interpret.” But conducting a third trial and running validity testing after FDA issued final PRO guidance, as well as key secondary endpoints that supported the treatment effect, helped sway regulators.